InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Berrey M Michelle, Président de la R&D. Officer active across 1 company, notably Intercept Pharmaceuticals, INC.. Cumulatively, 13 disclosures have been published. Activity tracked since 14 June 2021. The latest transaction was filed on 8 November 2023 (U). Regulator: SEC (Form 4). All data is free.
Declarations13 total
28,349 shares@ US$19.0076.9% of flowCommon StockSEC:0001104659-23-117115:0
1,246 shares@ US$11.572.1% of flowCommon StockSEC:0001104659-23-101573:0
1,246 shares@ US$12.042.1% of flowCommon StockSEC:0001104659-23-072210:0
1,246 shares@ US$15.792.8% of flowCommon StockSEC:0001104659-23-033307:0
14,700 shares0Common StockSEC:0001104659-23-008581:0
765 shares@ US$12.371.4% of flowCommon StockSEC:0001104659-23-000327:0
1,246 shares@ US$14.942.7% of flowCommon StockSEC:0001104659-22-127799:0
1,246 shares@ US$17.143.3% of flowCommon StockSEC:0001104659-22-100803:0
4,984 shares@ US$12.10100.0% of flowCommon StockSEC:0001104659-22-071868:0
10,300 shares0Common StockSEC:0001104659-22-009551:0
10,300 shares0Common StockSEC:0001104659-22-009551
67,118 shares0Common StockSEC:0001104659-21-081624
67,118 shares0Common StockSEC:0001104659-21-081624:0
13 of 13 declarations
About Berrey M Michelle
Michelle M. Berrey is President of R&D and Chief Medical Officer of Intercept Pharmaceuticals, Inc. In this role, she oversees the company's research and development initiatives. Michelle brings valuable expertise in the pharmaceutical sector, thereby contributing to the innovation and growth of Intercept Pharmaceuticals. Her commitment to scientific excellence is essential for the company.
